Neuron23 vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
$96.5M Series D (2025); NEU-411 LRRK2 inhibitor in Phase 2 NEULARK trial for early Parkinson's disease.
About
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. The company combines advances in human genetics with AI-based drug discovery and biomarker platforms to identify novel molecular targets and advance therapies for conditions with high unmet medical need. Its lead program, NEU-411, is a brain-penetrant, potent, and selective LRRK2 inhibitor targeting early Parkinson's disease.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.